Biotech Values

[DewDiligence]

PFE/BNTX COVID vaccine—>80% efficacy in young children—(age 6mo-5yr):

https://www.globenewswire.com/news-release/2022/05/23/2448240/0/en/Pfizer-BioNTech-COVID-19-Vaccine-Demonstrates-Strong-Immune-Response-High-Efficacy-and-Favorable-Safety-in-Children-6-Months-to-Under-5-Years-of-Age-Following-Third-Dose.html

The primary endpoint was prevention of symptomatic disease. The regimen tested against placebo consisted of three doses of 3mcg each (9mcg total). By comparison, the regimen of PFE’s vaccine for pre-adolescent older children (age 5-11) is 2 doses of 10mvg each (20mcg total). The adolescent/adult regimen is 2 doses of 30mcg each (60mcg total).

The above are interim data after 10 events (i.e. 10 cases of symptomatic COVID). The trial is slated to have a final analysis after 21 events, but the interim data may be sufficient for an FDA EUA.